Related Experiment Videos
[Clinical experience with bromperidol in chronic psychoses]
L E Bellomo1, N Rosset, L Tellarini
1Facultad de Medicina UBA, Buenos Aires, Argentina.
Acta Psiquiatrica Y Psicologica De America Latina
|September 1, 1988
Summary
Bromperidol (BP) is an effective and well-tolerated treatment for chronic psychotic patients, offering a convenient single daily dose. It presents a viable alternative to Haloperidol for managing schizophrenia and delusional disorders.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Chronic psychotic disorders require effective and well-tolerated long-term treatment options.
- Antipsychotic medications play a crucial role in managing conditions like schizophrenia and delusional disorders.
Purpose of the Study:
- To evaluate the therapeutic efficacy and tolerance of bromperidol (BP) in chronic psychotic female inpatients.
- To determine if BP is a suitable alternative to Haloperidol for specific psychiatric conditions.
Main Methods:
- A 3-month open-label trial was conducted on 25 female inpatients with chronic psychosis.
- Bromperidol was administered orally in a single nightly dose ranging from 10 to 35 mg.
Main Results:
- Bromperidol demonstrated efficacy and good tolerance in chronic psychotic patients.
- No significant effect was observed on periodic catatonia.
- The single daily dosage simplifies administration.
Conclusions:
- Bromperidol is a well-tolerated and effective option for chronic psychotic patients.
- BP is a suitable alternative to Haloperidol for schizophrenia and delusional disorders without deficitary evolution.
- The convenience of a single daily dose enhances patient compliance.